Genesis Therapeutics, based in Burlingame, California, is a trailblazing company in the field of AI-powered drug discovery. They have developed an advanced molecular AI platform that unlocks novel protein targets, explores untapped chemical space, and accelerates the development of critical new medicines.

The company is a tight-knit team of proven drug hunters, deep learning researchers, and software engineers collaborating to drive AI in biochemistry. Their pioneering approach to AI for biotech involves 3D spatial graph modeling and cutting-edge molecular simulation to generate novel drug candidates.

Genesis Therapeutics has raised significant funding and is approaching an inflection point with the first of their AI-enabled drug candidates entering the clinic. Their Genesis Exploration of Molecular Space (GEMS) platform uses generative and predictive AI technology to accelerate drug discovery. The platform can identify previously undruggable targets, opening up avenues for novel treatments.